Avacta Group plc Hits Clinical Candidate Selection Milestone for Affimer PD-L1 Inhibitor


CAMBRIDGE, England–(BUSINESS WIRE)–Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, announces that it has selected the clinical development candidate for first-time-in-human clinical trials of the Affimer platform. This important milestone means that the Group remains on track to submit an IND/CTA application for an Affimer PD-L1 inhibitor by the end of 2020. The Group has generated a wide range of Affimer inhibitors of PD-L1, a well known cancer…